ClinicalTrials.gg
Status unknownNCT00930007CRM005Updated May 18, 2022

Sleep-wake Changes of Luteinizing Hormone Frequency in Pubertal Girls With and Without High Testosterone

An observational study in Hyperandrogenism, sponsored by University of Virginia. Status unknown at 1 site in United States. Open to female participants aged 8 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-18.

Sponsored by University of Virginia · Observational

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
90
Ages
8 Years to 15 Years
Sex
Female
01

Study summary

The purpose of this study is to determine whether sleep-wake changes of luteinizing hormone pulse frequency are different in early pubertal girls with high testosterone levels compared to early pubertal girls with normal testosterone levels.

Read the detailed description

During early puberty, luteinizing hormone (LH) pulse frequency normally increases during sleep. In contrast, preliminary data suggest that obese girls (who have high testosterone levels in general) demonstrate low LH frequency during the day and night during early puberty; but at mid puberty rapidly transition to a high LH frequency during the day and night. We hypothesize that in early pubertal girls with high testosterone levels, overnight increases of LH frequency are less prominent than those observed in early pubertal girls with normal testosterone levels. We will assess this using a frequent sampling protocol for assessment of LH pulse frequency (with sampling occurring while awake and while asleep) in early pubertal girls with and without high testosterone levels. Sleep will be formally evaluated.

02

Conditions studied

  • Hyperandrogenism

Browse trials for

Keywords

  • Luteinizing hormone
  • Puberty
03

In context

Hyperandrogenism

81 studies on the registry are indexed under Hyperandrogenism; 22 are open to participants now.

This study's planned enrollment of 90 is below the median of 135 across 26 observational studies indexed under Hyperandrogenism.

Browse Hyperandrogenism studies →

Lead sponsor

University of Virginia is the lead sponsor of 675 studies on the registry; 138 are open to participants now.

Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 15 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Community sample and patients from local clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Early to midpubertal girls (late Tanner 1 [i.e., estradiol > 20 pg/ml] to Tanner 3)
  • Premenarcheal
  • Approximate ages, 8-15 years

Exclusion criteria

Exclusion Criteria:

  • -for-age \< 5th percentile
  • Inability to comprehend what will be done during the study or why it will be done
  • Being a study of GnRH pulse regulation in adolescent girls with and without HA, boys are excluded
  • Obesity associated with a diagnosed (genetic) syndrome (e.g., Prader-Willi syndrome, leptin deficiency), obesity related to medications (e.g., ), etc.
  • Pregnancy or lactation
  • Virilization
  • Total testosterone > 150 ng/dl (confirmed on repeat)
  • DHEAS > upper limit of age-appropriate normal range (confirmed on repeat) (mild elevations may be seen in adolescent HA, and elevations \< 1.5 times the age-appropriate will be accepted in such girls)
  • Follicular phase 17-hydroxyprogesterone > 250 ng/dl (for girls \< 12 years old) or > 300 ng/dl (for girls 12 and older) (confirmed on repeat), which suggests the possibility of congenital adrenal hyperplasia. NOTE: If an elevated follicular 17-hydroxyprogesterone is confirmed on repeat testing, an ACTH stimulated 17-hydroxyprogesterone \< 1000 ng/dl will be required for study participation
  • History of premature adrenarche (i.e., appearance of pubic and/or axillary hair before age 8)
  • A previous diagnosis of diabetes
  • Fasting glucose ≥ 126 mg/dl, or a > 6.5% (confirmed on repeat)
  • Abnormal TSH (confirmed on repeat) (subjects with adequately treated hypothyroidism, reflected by normal TSH values, will not be excluded)
  • Abnormal prolactin (confirmed on repeat) (mild elevations may be seen in HA girls, and elevations \< 1.5 times the upper limit of normal will be accepted in this group)
  • Evidence of Cushing's syndrome by history or physical exam (e.g., history of impaired growth in children, striae)
  • Hematocrit \< 36% and \< 12 g/dl (confirmed on repeat)
  • Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.)
  • Persistent liver test abnormalities (confirmed on repeat), with the exception that mild elevations will be accepted in the setting of known Gilbert's syndrome
  • Persistently abnormal sodium, potassium, or elevated creatinine concentration (confirmed on repeat)
  • Bicarbonate concentrations \< 20 or > 30 (confirmed on repeat)
  • No medications known to affect the reproductive system, glucose metabolism, lipid metabolism, or blood pressure can be taken in the 3 months prior to the first inpatient GCRC study (or in the 2 months prior to screening)

    • Such medications include oral pills, progestins, metformin, glucocorticoids, psychotropics, and sympathomimetics/stimulants (e.g., methylphenidate)
    • Patients taking restricted medications will be excluded unless written permission (for the subjects to discontinue the medication) is received from the subject's physician
  • Weight \< 22 kg is an absolute exclusion criterion (to ensure safe blood withdrawal)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
90 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Hyperandrogenemic

    Girls with elevated free testosterone concentrations

    Other: Blood sampling

  • Controls

    Girls with normal free testosterone concentrations

    Other: Blood sampling

Interventions

  • OtherBlood sampling

    Blood sampling for later hormone measurements

06

What researchers measure

Primary outcomes

  1. Luteinizing hormone pulse frequency (while awake and while asleep)

    Time frame: Baseline (time zero)

Secondary outcomes

  1. Progesterone concentration

    Time frame: Baseline (time zero)

  2. Estradiol concentration

    Time frame: Baseline (time zero)

  3. Testosterone concentrations

    Time frame: Baseline (time zero)

  4. Luteinizing hormone amplitude

    Time frame: Baseline (time zero)

  5. Sleep stage parameters

    Time frame: Baseline (time zero)

07

Study locations

1 site
  • University of Virginia
    Charlottesville, Virginia 22908, United States
08

References and documents

Individual participant data

Plan to share: Undecided — We do not have current plans to share IPD

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00930007
Responsible party
Chris McCartney (Associate Professor of Medicine, University of Virginia) — Principal investigator
First posted
Jun 30, 2009
Start date
Oct 2008
Primary completion
May 2023 (estimated)
Completion
Aug 2023 (estimated)
Last update
May 18, 2022

Study contacts

Christopher R McCartney, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion